F J Esteva

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi HER2 therapy: molecular mechanisms of trastuzumab resistance
    Rita Nahta
    Department of Breast Medical Oncology, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030 4009, USA
    Breast Cancer Res 8:215. 2006
  2. ncbi Prognostic molecular markers in early breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:109-18. 2004
  3. ncbi Optimizing outcomes in HER2-positive breast cancer: the molecular rationale
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center Houston, Texas 77030, USA
    Oncology (Williston Park) 19:5-16. 2005
  4. ncbi Molecular prognostic factors for breast cancer metastasis and survival
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:319-28. 2002
  5. ncbi Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 5768, USA
    Oncologist 9:4-9. 2004
  6. ncbi Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
  7. ncbi A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Cancer 98:900-7. 2003
  8. ncbi Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
  9. ncbi Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer
    Windy Dean-Colomb
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 35:S31-8; quiz S40. 2008
  10. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007

Research Grants

  1. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003

Detail Information

Publications92

  1. ncbi HER2 therapy: molecular mechanisms of trastuzumab resistance
    Rita Nahta
    Department of Breast Medical Oncology, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030 4009, USA
    Breast Cancer Res 8:215. 2006
    ..We also discuss novel therapies that may improve the efficacy of trastuzumab, and that offer hope that the survival of breast cancer patients with HER2-overexpressing tumors can be vastly improved...
  2. ncbi Prognostic molecular markers in early breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:109-18. 2004
    ..RT-PCR has also been used to evaluate expression of multiple genes in archival tissue. Proteomics technologies are in development...
  3. ncbi Optimizing outcomes in HER2-positive breast cancer: the molecular rationale
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center Houston, Texas 77030, USA
    Oncology (Williston Park) 19:5-16. 2005
    ..Optimizing the use of therapies that target HER2 signaling will lead to further advances in the treatment of breast cancer...
  4. ncbi Molecular prognostic factors for breast cancer metastasis and survival
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:319-28. 2002
    ..We review the available data supporting the utility of established prognostic and predictive molecular factors, and discuss challenges for integrating novel molecular markers into clinical practice...
  5. ncbi Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 5768, USA
    Oncologist 9:4-9. 2004
    ..Optimum combination therapy regimens with a variety of novel approaches that incorporate small molecule targeted therapies need to be developed, and the population most likely to benefit from targeted therapies needs to be identified...
  6. ncbi Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J Esteva
    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 7:R436-43. 2005
    ..We also sought to determine whether early changes in serum HER2/neu concentrations could be a predictor of progression-free survival...
  7. ncbi A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Cancer 98:900-7. 2003
    ..The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma...
  8. ncbi Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  9. ncbi Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer
    Windy Dean-Colomb
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 35:S31-8; quiz S40. 2008
    ....
  10. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  11. ncbi Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3315-9. 2005
    ..A secondary objective was to determine whether the quantitative RT-PCR data correlated with immunohistochemistry assay data regarding estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status...
  12. ncbi The current status of docetaxel for metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:17-26. 2002
    ..The consistent demonstration of a high level of efficacy with manageable toxicity ensures the continued widespread investigation of docetaxel in metastatic breast cancer...
  13. ncbi Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, Texas 77030, USA
    Breast 15:301-12. 2006
    ..The effects of the other AIs on lipid levels are variable, and any correlation with cardiovascular events is currently unknown...
  14. ncbi Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 1354, Houston, Texas 77030, USA
    Oncologist 13:370-2. 2008
  15. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  16. ncbi Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5652-9. 2003
    ....
  17. ncbi Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 56, Houston, TX 77030, USA
    Oncologist 6:133-46. 2001
    ..Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer...
  18. ncbi Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:499-506. 2004
    ....
  19. ncbi Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
    F Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:315-20. 2008
    ..We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues...
  20. ncbi Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab
    F Peintinger
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Oncol 19:2020-5. 2008
    ....
  21. ncbi Survival among women with triple receptor-negative breast cancer and brain metastases
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 20:621-7. 2009
    ..The purpose of this study was to determine the incidence of and survival following brain metastases among women with triple receptor-negative breast cancer...
  22. ncbi Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy
    T A Buchholz
    Departments of Radiation Oncology, Biomathematics, Breast Medical Oncology, and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2240-6. 2001
    ..To determine the impact of tamoxifen and chemotherapy on local control for breast cancer patients treated with breast-conservation therapy...
  23. ncbi Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry
    F J Esteva
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA
    Pathol Oncol Res 7:171-7. 2001
    ..Further research is needed to determine the prognostic and predictive roles of the various associations between HER receptors, their ligands and signal transduction molecules in patients with early-stage breast cancer...
  24. ncbi Adjuvant systemic therapy for primary breast cancer
    F J Esteva
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
    Surg Clin North Am 79:1075-90. 1999
    ..Molecular markers of response may assist in drug selection in the adjuvant setting. Development of novel therapeutic agents continues based on an expanded biologic understanding of tumor development and progression...
  25. ncbi P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer Res 64:3981-6. 2004
    ..Thus, we propose that trastuzumab resistance may be associated with decreased p27(kip1) levels and may be susceptible to treatments that induce p27(kip1) expression...
  26. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  27. ncbi Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule
    Fadi Estephan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Tex, USA
    Oncology 77:63-70. 2009
    ..A phase I study was initiated to determine the maximum tolerated dose (MTD) of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic breast carcinoma (MBC)...
  28. ncbi Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Cancer Invest 22:248-56. 2004
    ..However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy...
  29. ncbi Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  30. ncbi Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
    Fan Zhang
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1758-65. 2003
    ..CONCLUSIONS: The authors found no significant correlation between HER-2 expression and clinical or pathologic response to neoadjuvant chemotherapy in patients with breast carcinoma...
  31. ncbi In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA
    Cancer Chemother Pharmacol 53:186-90. 2004
    ..A randomized clinical trial of trastuzumab plus vinorelbine versus vinorelbine alone should be conducted in patients with HER-2-overexpressing breast cancer to determine the optimal duration of trastuzumab therapy upon progression...
  32. ncbi Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:7381-8. 2009
    ..To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS)...
  33. ncbi Defining prognosis for women with breast cancer and CNS metastases by HER2 status
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:1242-8. 2008
    ....
  34. ncbi Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer Res 65:11118-28. 2005
    ....
  35. ncbi Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ophthalmology 109:1188-91. 2002
    ..Once complete or near complete stenosis of the canaliculi occurs, placement of a permanent Pyrex glass tube may become necessary to overcome the blockage of tear outflow...
  36. ncbi Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer
    Dongwei Zhang
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:6639-48. 2009
    ..Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway...
  37. ncbi Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4107-15. 2006
    ..In patients who have experienced a CE, additional treatment with trastuzumab can be considered after recovery of cardiac function...
  38. ncbi Gaining ground on breast cancer
    Francisco J Esteva
    University of Texas M.D. Anderson Cancer Center, TX, USA
    Sci Am 298:58-65. 2008
  39. ncbi Growth factor receptors in breast cancer: potential for therapeutic intervention
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 8:5-17. 2003
    ..Biologic therapies directed against these important receptors are promising. In this review we discuss challenges and opportunities for the development of growth-factor-targeted approaches for the treatment of breast cancer...
  40. ncbi Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
    E Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 19:1716-22. 2001
    ..We conducted a single-institution phase I clinical trial to determine the maximum-tolerated dose (MTD) and define the toxic effects of stealth liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer...
  41. ncbi PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1802-11. 2010
    ..To determine the role of PEA-15 in breast cancer...
  42. ncbi Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)
    Ricardo J Gonzalez
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 13:72-5. 2007
    ....
  43. ncbi Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer
    Daniel J Lenihan
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 13:1224-34. 2008
    ..Because of the multimodal treatment of EBC patients, their care requires a multidisciplinary approach to reduce not only the risk for breast cancer recurrence but also the risk for treatment-related cardiac toxicities...
  44. ncbi Her2-positive breast cancer: herceptin and beyond
    Windy Dean-Colomb
    Department of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Cancer 44:2806-12. 2008
    ....
  45. ncbi Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
    Dongwei Zhang
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1846-50. 2008
    ..We conclude that the in vitro activity of lapatinib is not dependent on EGFR expression level in HER2-overexpressing breast cancer cells...
  46. ncbi Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
    Hiroaki Itamochi
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 448, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:227-35. 2007
    ..001). E1A gene therapy, because of its ability to stabilize wild-type p53, is worth exploring as a treatment modality for women with ovarian CCC, which typically expresses wild-type p53...
  47. ncbi Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
    Jianzhou Wang
    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:3107-14. 2002
    ....
  48. ncbi Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:258-63. 2004
    ..45 and P = 0.14, respectively). CONCLUSIONS: her-2 gene amplification was not found to be predictive of a pathologic response to preoperative taxanes in patients with early-stage breast carcinoma...
  49. ncbi Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 30:143-9. 2003
    ..Phase III randomized clinical trials are ongoing in patients with solid tumors. Bcl-2 antisense-based therapy represents a viable strategy for inducing apoptosis and enhancing the chemosensitivity of breast cancers...
  50. ncbi Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells
    Ana M Tari
    Department of Bioimmunotherapy, Section of Immunobiology and Drug Carriers, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, TX 77030, USA
    Oncogene 21:5224-32. 2002
    ..ATRA sensitivity was also correlated with RARalpha protein levels since higher RARalpha protein levels were observed in cells in which the Her2/neu pathway was inhibited...
  51. ncbi Signal transduction inhibitors in the treatment of breast cancer
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Curr Med Chem Anticancer Agents 3:201-16. 2003
    ..Current evidence suggests that targeting of signaling molecules is a promising new approach to treatment of breast cancer...
  52. ncbi Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions
    Doina Ivan
    Department of Pathology, University of Texas, Houston, TX, USA
    Mod Pathol 17:811-8. 2004
    ..Also, the relative high expression of Jab1 in metastatic melanoma, associated with low levels of p27, suggests that Jab1 may be involved in survival and proliferation of metastatic melanoma cells...
  53. ncbi Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7909-16. 2008
    ..We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)...
  54. ncbi Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer
    X He
    Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:1771-80. 2012
    ....
  55. ncbi Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer
    Michael Z Gilcrease
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 33:759-67. 2009
    ....
  56. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  57. ncbi Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:39-47. 2011
    ..Through this study, the authors sought to investigate the biologic and immunologic effects of preoperative trastuzumab in patients with ductal carcinoma in situ (DCIS) of the breast...
  58. ncbi Breast carcinoma treatment received by women with disabilities compared with women without disabilities
    Mabel E Caban
    Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas 77046, USA
    Cancer 94:1391-6. 2002
    ..To the authors' knowledge, there are no data to support the hypothesis that disabled women are diagnosed at a more advanced stage of disease compared with women without disabilities...
  59. ncbi Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
    ..The authors also compared the plasma profiles of patients with cancer with the plasma profiles of healthy women to identify breast carcinoma-associated protein markers...
  60. ncbi Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
    Chien Hsing Lu
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5883-8. 2007
    ..Here, we did preclinical studies on the efficacy of clinically applicable inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway to restore trastuzumab sensitivity to PTEN-deficient cells...
  61. ncbi The use of HER2 modulation in the adjuvant setting
    Peter H Johnson
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77230 1439, USA
    Curr Oncol Rep 9:9-16. 2007
    ..The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy...
  62. ncbi Molecular predictors of response to trastuzumab and lapatinib in breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Nat Rev Clin Oncol 7:98-107. 2010
    ..In the future, it will be important to characterize mechanisms of resistance in metastatic tumors to determine which novel targeted therapy will be most appropriate for individual patients...
  63. ncbi Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
    Rita Nahta
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:667-74. 2007
    ..As increased IGF-I receptor signaling has been implicated in trastuzumab resistance, our data strongly support further study of lapatinib as a potential therapeutic in breast cancers that have progressed on trastuzumab...
  64. ncbi Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 3:269-80. 2006
    ..Novel therapies targeted against these aberrant molecular pathways offer hope that the effectiveness and duration of response to trastuzumab can be greatly improved...
  65. ncbi Tamoxifen-related vasculitis
    Mauricio Z Baptista
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 24:3504-5. 2006
  66. ncbi Herceptin: mechanisms of action and resistance
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
    Cancer Lett 232:123-38. 2006
    ..This review describes mechanisms by which Herceptin inhibits cell growth in breast cancers that overexpress HER-2 and highlights possible mechanisms contributing to Herceptin resistance...
  67. ncbi Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?
    Yu Shen
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 447, Houston, TX 77030, USA
    Breast Cancer Res Treat 102:347-56. 2007
    ..To determine the influence of race on breast cancer treatment and on recurrence and breast cancer specific death...
  68. ncbi Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
    Quanri Jin
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res 12:R96. 2010
    ..We hypothesized that FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells...
  69. ncbi Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
    Ke Liang
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:423-35. 2010
    ....
  70. ncbi Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy
    Funda Meric-Bernstam
    Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 6:357-60. 2005
  71. ncbi Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Chemother Pharmacol 49:299-302. 2002
    ..We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil...
  72. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  73. ncbi Neoadjuvant chemotherapy
    Marjorie C Green
    Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 21:23-31. 2004
  74. ncbi Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Ander son Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, Texas 77030, USA
    Oncologist 11:857-67. 2006
    ..Here, we review the recently completed clinical trials of adjuvant trastuzumab in the adjuvant setting. HER-2/neu testing, patient selection, cardiotoxicity, duration of therapy, and directions for future research are discussed...
  75. ncbi Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 24:187-91. 2006
    ....
  76. ncbi Helicobacter pylori bacteremia with sepsis syndrome
    Xiang Y Han
    Department of Laboratory Medicine, Unit 84, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Microbiol 48:4661-3. 2010
    ..Initial subculture failed, but the organism was identified as Helicobacter pylori by sequencing the 16S rRNA gene. The bacterium eventually grew on brucella agar upon extended incubation...
  77. ncbi Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
    Daniel J Booser
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, Texas 77030 4095, USA
    Cancer Chemother Pharmacol 50:6-8. 2002
    ..L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer...
  78. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  79. ncbi Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1439, USA
    Clin Breast Cancer 7:326-30. 2006
    ..The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC)...
  80. ncbi Residual risk of breast cancer recurrence 5 years after adjuvant therapy
    Abenaa M Brewster
    Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:1179-83. 2008
    ..Breast cancer patients have a substantial residual risk of recurrence, and selected tumor characteristics are associated with late recurrences...
  81. ncbi Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  82. ncbi B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 5:1593-601. 2006
    ..These results suggest that BTG1 is a Bcl-2-regulated mediator of apoptosis in breast cancer cells, and that its induction contributes to antisense Bcl-2-mediated cytotoxic effects...
  83. ncbi Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 141:148-53. 2003
    ..Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics...
  84. ncbi Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
    Lajos Pusztai
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 009, USA
    Clin Cancer Res 9:2406-15. 2003
    ..33)P]dCTP-labeled cDNA probes were generated and hybridized to cDNA membrane microarrays that contained 30,000 human sequence clones, including 10,890 expressed sequence tags...
  85. ncbi Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
    Phuong Khanh H Morrow
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 11:207. 2009
    ....
  86. ncbi Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
    Y Delpech
    1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Gynecology and Obstetrics, Lariboisiere Hospital, AP HP, Paris, France
    Br J Cancer 108:285-91. 2013
    ..Pathological complete responses are rare in both groups, but do not significantly differ after adjusting for other variables...
  87. ncbi Trastuzumab: triumphs and tribulations
    R Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Oncogene 26:3637-43. 2007
    ..Molecular mechanisms of trastuzumab antineoplastic activity and potential mechanisms contributing to its resistance will be discussed in this review. Novel agents that may enhance trastuzumab efficacy will also be discussed...
  88. ncbi Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer
    Alberto Ocana
    Hospital Universitario de Salamanca, Dalamanca, Spain
    Clin Breast Cancer 6:495-504. 2006
    ..Prospective studies are needed in order to validate the clinical utility of novel markers of response to specific chemotherapies and/or various schedules of administration...
  89. ncbi The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer Res 64:2343-6. 2004
    ..These results suggest that combining HER-2-targeting agents may be a more effective therapeutic strategy in breast cancer rather than treating with a single HER-2 monoclonal antibody...
  90. ncbi HER-2-targeted therapy: lessons learned and future directions
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Clin Cancer Res 9:5078-84. 2003
    ..This minireview describes HER-2 targeting strategies currently in use or in stages of development for the treatment of breast cancer...
  91. ncbi Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    Suhail M Ali
    Department of Hematology Oncology, Penn State Hershey Cancer Center, Penn State University Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Cancer 113:1294-301. 2008
    ..The objectives of this study were to pool data from 307 patients with MBC from 7 medical institutions to validate that the serum HER-2/neu profile predicts patient resistance to trastuzumab and to establish a clinically relevant cutoff...
  92. ncbi Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Francisco J Esteva
    J Natl Cancer Inst 100:521-3. 2008

Research Grants1

  1. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003
    ..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..